A Phase 2 interventional study of rMenB and rMenB+OMV NZ in Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 1 site in United Kingdom. Open to participants aged 40 Months to 62 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-01.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 16th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 2, and was the 7th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 40 Months to 62 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 9 · Phase 4 4
First in 2006; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is below the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 508 across the 21 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
60 studies in Meningococcal Infections by Novartis: none open now, none under way, none of them phase 3. Of 59 finished, 48 (81%) have results posted.
Among the 60 studies in Meningococcal Infections by Novartis, this one is the 51st largest by enrollment of the 57 interventional ones that give a count, is one of 8 that started in 2010, is one of 21 in phase 2, and was the 33rd registered.
Novartis’s Meningococcal Infections studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 60 in Meningococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The proposed study V72P9E1 is an Extension Study of V72P9. The objectives of this extension study will be to explore antibody persistence in children at approximately 40 months of age and to evaluate the safety, tolerability and immunogenicity of a booster dose of rMenB±OMV NZ administered to subjects at approximately 40 months of age. Antibody persistence will be subsequently measured at 18-20 months after these booster doses when the subjects are 60 months of age. Two groups of naïve subjects, aged approximately 40 and 60 months, will be recruited in the study to serve as a baseline comparator for assessing antibody persistence at these ages. These subjects will receive a two-dose catch-up regimen with rMenB+OMV NZ. Subjects who are enrolled at 40 months of age are offered DTaP/IPV and MMR vaccinations , if they have not already received these vaccines prior to enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received three primary doses of rMenB vaccine (at the age of 6-8 months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB vaccine at 40 months of age in the present study.
Biological: rMenB
Subjects received three primary doses of rMenB+OMV NZ vaccine (at the age of 6-8months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB+OMV NZ vaccine at 40 months of age in the present study.
Biological: rMenB+OMV NZ
Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.
Biological: rMenB+OMV NZ
Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study.
Biological: rMenB+OMV NZ
Drug page: 4CMenB vaccine
Persistence of Serum Bactericidal Antibody Titers in Children (at 40 Months of Age), Twenty-eight Months After Completing Primary Vaccination.
The geometric mean antibody titers (GMTs) against Neisseria meningitidis serogroup B in children (at 40 months of age); twenty-eight months after completion of primary vaccination with either rMenB or rMenB+OMV NZ vaccines, are compared with the GMTs in vaccine-naïve children.
Time frame: 28 months after primary vaccination; Baseline for Naïve
Percentage of Subjects With Persisting Serum Bactericidal Antibodies Titers ≥4, Twenty-eight Months After Completing Primary Vaccination.
The percentages of subjects with persisting serum bactericidal antibodies (hSBA) titers ≥4, against N meningitidis serogroup B at 40 months of age; twenty-eight months after completion of primary vaccination with either rMenB or rMenB+OMV NZ as compared to the vaccine-naïve children are reported. The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA).
Time frame: 28 months after primary vaccination; Baseline for Naïve
Number of Subjects Reporting Solicited Local and Systemic Adverse Events After a Booster Dose of rMenB or rMenB+OMV NZ Vaccine at Forty Months of Age.
The safety and tolerability of a single booster dose of rMenB or rMenB+OMV NZ vaccine in 40 month old children who had previously received three primary doses of the same vaccine as infants in parent study was assessed in terms of number of subjects with solicited local and systemic reactions following vaccination and compared to tolerability in vaccine-naive children who received 1st catch-up dose of rMenB+OMV NZ at 40 months of age.
Time frame: Day 1 to Day 7 [after booster vaccination /post dose 1 for naive]
Serum Bactericidal Antibody Titers in Children After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age
The serum bactericidal antibody response one month after a booster dose of rMenB or rMenB+OMV NZ vaccine was given to children at 40 months of age is compared with the antibody titers following one catch-up dose rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects and reported as GMTs.
Time frame: 1 month post booster /1 month post dose 1 for Naïve
Percentage of Subjects With Serum Bactericidal Antibody Titers ≥4 After Receiving a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age
The percentages of subjects with hSBA titers ≥4 against N meningitidis serogroup B one month after receiving a single booster dose of rMenB or rMenB+OMV NZ vaccine at 40 months of age, is compared with hSBA response following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months in vaccine-naive subjects.
Time frame: 1 month post-booster/ 1 month post-dose 1 for Naïve
Percentage of Subjects With a 4-fold Increase in Antibody Titers After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age
The percentages of subjects with four-fold increase in hSBA titers over baseline against N meningitidis serogroup B, one month after receiving a single booster dose of rMenB or rMenB+OMV NZ vaccine at 40 months of age, and compared with 4-fold increase in hSBA titers following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects. Baseline was defined as either the time that the (first) booster dose was given (i.e. at 40 months of age) or the time of the first vaccination (i.e. at 40 months of age for Naive_4042 group.
Time frame: 1 month post booster / 1 month post dose 1 for Naïve
Persistence of Serum Bactericidal Antibody Titers in Children (at 60 Months of Age), Twenty Months After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine
The persisting serum bactericidal antibody titers in children (at 60 months of age), twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months of age) is compared with the antibody titers in vaccine -naïve subjects of the same age and reported as GMTs.
Time frame: 20 months post booster/ Baseline for Naïve
Percentage of Subjects With Persisting Serum Bactericidal Antibody Titers ≥4, Twenty Months After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine
The percentage of subjects (60 months of age) with persisting hSBA titers ≥4, twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months of age) are compared with hSBA response in vaccine-naïve subjects of the same age.
Time frame: 20 months post booster/ Baseline for Naïve
Percentage of Subjects With Serum Bactericidal Antibody Titers ≥4 Following Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age
The percentage of subjects with hSBA titers ≥4 after two catch-up doses of rMenB+OMV NZ vaccine when given either at- 40 \& 42 months or 60 \& 62 months of age is reported.
Time frame: 1 month post -vaccine dose two
Serum Bactericidal Antibody Titers in Children Following Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age.
The serum bactericidal antibody response in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at- 40 \& 42 months or 60 \& 62 months of age are reported as GMTs.
Time frame: 1 month post vaccine dose two
Percentage of Subjects With a 4-fold Increase in Antibody Titers After Two Catch up Doses of rMenB+OMV NZ Vaccine Given One Month Apart Either at 40 or 60 Months of Age
The percentages of subjects with four-fold increase in hSBA titers over baseline against N meningitidis serogroup B one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 \& 42 months or 60 \& 62 months of age.
Time frame: 1 month post vaccine dose 2
Persistence of Serum Bactericidal Antibody Titers in Children (at 60 Months), Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.
The serum bactericidal antibody response in children at 60 months of age who had received two catch-up doses of rMenB+OMV NZ vaccine at- 40 \& 42 months age is reported as GMTs.
Time frame: 18 months post vaccine dose 2
Percentage of Subjects With Serum Bactericidal Antibody Titers ≥4, Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.
Persisting hSBA titers ≥4 in children at 60 months of age, who had received two catch-up doses of rMenB+OMV NZ vaccine at 40 \& 42 months age is reported.
Time frame: 18 months post vaccine dose two
Geometric Mean Antibody Concentrations in Children (at 40 Months of Age), Twenty Eight Months After Completing Primary Vaccination.
The persisting geometric mean antibody concentrations (GMCs) against vaccine antigen 287-953 in children (at 40 months of age), twenty-eight months after completion of primary vaccination with either rMenB or rMen+OMV NZ vaccines, are compared with the GMCs in vaccine-naïve children. GMCs against vaccine antigen 287-953 were measured using enzyme linked immunosorbent assay (ELISA).
Time frame: 28 months after primary vaccination/ Baseline for Naïve
Geometric Mean Antibody Concentrations in Children, After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age.
The GMCs against vaccine antigen 287-953, in children one month after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccine , is compared with GMCs following one catch-up dose of rMenB+ OMV NZ in children at 40 months.
Time frame: 1 month post booster /1 month post dose 1 for Naïve
Geometric Mean Antibody Concentrations in Children (at 60 Months of Age), Twenty Months After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine
The persisting GMCs against vaccine antigen 287-953 in children (at 60 months of age), twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months), are compared with GMCs in vaccine-naïve children of same age.
Time frame: 20 months post booster/ Baseline for Naïve
Geometric Mean Antibody Concentrations in Children After Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 Months or 60 Months of Age.
The GMCs against vaccine antigen 287-953 in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at 40- \& 42- months or 60- \& 62- months of age are reported.
Time frame: 1 month post vaccine dose two
Geometric Mean Antibody Concentrations in Children (at 60 Months), Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine.
Persistence of GMCs against vaccine antigen 287-953 in children (60 months of age), eighteen months after two catch-up doses of rMenB+OMV NZ vaccine given at 40 months of age.
Time frame: 18 months post vaccine dose 2
Percentage of Subjects With Four Fold Increase in Geometric Mean Antibody Concentrations , After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age
The percentage of subjects with four fold increase in GMCs over baseline against vaccine antigen 287-953 one month after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccine, is compared with responses following one catch-up dose of rMenB+OMV NZ in children at 40 months.
Time frame: 1 month post booster / 1 month post dose 1
Percentage of Subjects With 4-fold Increase in Geometric Mean Antibody Concentrations, After Two Catch-up Doses of rMenB+OMV NZ Vaccine Given One Month Apart Either at 40 or 60 Months of Age
The percentages of subjects with four-fold increase in GMCs over baseline against vaccine antigen 287-953, one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 \& 42 months or 60 \& 62 months of age.
Time frame: 1 month post dose 2
Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine One Month Apart, Either at 40 or 60 Months of Age
The safety and tolerability of a two doses of rMenB+OMV NZ vaccine in children when given either at 40 \& 42 months or 60 \& 62 months of age is assessed in terms of number of subjects with solicited local and systemic reactions following vaccination.
Time frame: Day 1-7 after each vaccination
Subjects were recruited from a single center.
| Milestone | 4rMenB | 4rMenB+OMV NZ | Naive_4042 | Naive_6062 |
|---|---|---|---|---|
| Started | 16 | 14 | 41 | 49 |
| Completed | 15 | 12 | 29 | 46 |
| Not completed | 1 | 2 | 12 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 | 7 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 | 4 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Inappropriate enrollment | 0 | 0 | 1 | 0 |
The geometric mean antibody titers (GMTs) against Neisseria meningitidis serogroup B in children (at 40 months of age); twenty-eight months after completion of primary vaccination with either rMenB or rMenB+OMV NZ vaccines, are compared with the GMTs in vaccine-naïve children.
| Titers | 4rMenB | 4rMenB+OMV NZ | Naive_4042 |
|---|---|---|---|
| 44/76-SL strain (N = 14,14,39) | 1.26 (0.9 to 1.76) | 2.55 (1.15 to 5.66) | 1.08 (0.97 to 1.2) |
| 5/99 strain (N = 14,14,40) | 41 (18 to 95) | 29 (18 to 47) | 1 (1 to 1) |
| NZ98/254 strain (N = 15,14,39) | 1 (1 to 1) | 1.74 (0.91 to 3.33) | 1 (1 to 1) |
| M10713 strain ( N = 14,14,40) | 3.6 (1.32 to 9.84) | 7.11 (3.61 to 14) | 4.82 (2.9 to 8) |
The serum bactericidal antibody response one month after a booster dose of rMenB or rMenB+OMV NZ vaccine was given to children at 40 months of age is compared with the antibody titers following one catch-up dose rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects and reported as GMTs.
| Titers | 4rMenB | 4rMenB+OMV NZ | Naive_4042 |
|---|---|---|---|
| 44/76-SL strain (N = 13,14,39) | 100 (50 to 200) | 114 (59 to 222) | 8.89 (5.83 to 14) |
| 5/99 strain (N=14, 14, 39) | 1007 (445 to 2277) | 926 (432 to 1988) | 27 (16 to 44) |
| NZ98/254 strain (N=14, 14, 39) | 2.15 (0.88 to 5.23) | 32 (14 to 71) | 1.91 (1.35 to 2.71) |
| M10713 strain (N = 13,14,39) | 10 (3.43 to 30) | 23 (13 to 41) | 6.04 (3.73 to 9.79) |
The percentages of subjects with persisting serum bactericidal antibodies (hSBA) titers ≥4, against N meningitidis serogroup B at 40 months of age; twenty-eight months after completion of primary vaccination with either rMenB or rMenB+OMV NZ as compared to the vaccine-naïve children are reported. The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA).
| percentages of subjects | 4rMenB | 4rMenB+OMV NZ | Naive_4042 |
|---|---|---|---|
| 44/76-SL strain (N = 14,14,39) | 14 (2 to 43) | 36 (13 to 65) | 3 (0.065 to 13) |
| 5/99 strain (N = 14,14,40) | 93 (66 to 100) | 100 (77 to 100) | 0 (0 to 9) |
| NZ98/254 strain (N = 15,14,39) | 0 (0 to 22) | 14 (2 to 43) | 0 (0 to 9) |
| M10713 strain (N = 14,14,40) | 29 (8 to 58) | 79 (49 to 95) | 53 (36 to 68) |
The safety and tolerability of a single booster dose of rMenB or rMenB+OMV NZ vaccine in 40 month old children who had previously received three primary doses of the same vaccine as infants in parent study was assessed in terms of number of subjects with solicited local and systemic reactions following vaccination and compared to tolerability in vaccine-naive children who received 1st catch-up dose of rMenB+OMV NZ at 40 months of age.
| participants | 4rMenB | 4rMenB+OMV NZ | Naive_4042 |
|---|---|---|---|
| Local | 14 | 14 | 38 |
| Injection-site pain | 10 | 12 | 34 |
| Injection-site erythema | 13 | 14 | 36 |
| Injection-site swelling | 9 | 6 | 10 |
| Injection-site induration | 11 | 5 | 17 |
| Systemic | 12 | 11 | 30 |
| Change in eating habits | 5 | 5 | 13 |
| Sleepiness | 6 | 6 | 20 |
| Vomiting | 0 | 2 | 1 |
| Diarrhea | 2 | 1 | 2 |
| Irritability | 8 | 11 | 24 |
| Headache | 2 | 1 | 4 |
| Arthralgia | 2 | 3 | 9 |
| Rash | 2 | 1 | 2 |
| Fever (≥38°C) | 4 | 1 | 6 |
| Other | 6 | 10 | 21 |
| Temperature (≥40°C) | 0 | 0 | 1 |
| Antipyretic preventive medication used | 4 | 9 | 19 |
| Antipyretic treatment medication used | 3 | 1 | 5 |
| Medically attended fever | 0 | 0 | 0 |
The percentages of subjects with hSBA titers ≥4 against N meningitidis serogroup B one month after receiving a single booster dose of rMenB or rMenB+OMV NZ vaccine at 40 months of age, is compared with hSBA response following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months in vaccine-naive subjects.
| percentages of subjects | 4rMenB | 4rMenB+OMV NZ | Naive_4042 |
|---|---|---|---|
| 44/76-SL strain (N = 13, 14, 39) | 100 (75 to 100) | 100 (77 to 100) | 72 (55 to 85) |
| 5/99 strain (N=14, 14, 39) | 100 (77 to 100) | 100 (77 to 100) | 87 (73 to 96) |
| NZ98/254 strain (N=14, 14, 39) | 21 (5 to 51) | 93 (66 to 100) | 23 (11 to 39) |
| M10713 strain (N = 13, 14, 39) | 69 (39 to 91) | 93 (66 to 100) | 62 (45 to 77) |
The percentages of subjects with four-fold increase in hSBA titers over baseline against N meningitidis serogroup B, one month after receiving a single booster dose of rMenB or rMenB+OMV NZ vaccine at 40 months of age, and compared with 4-fold increase in hSBA titers following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects. Baseline was defined as either the time that the (first) booster dose was given (i.e. at 40 months of age) or the time of the first vaccination (i.e. at 40 months of age for Naive_4042 group.
| percentages of subjects | 4rMenB | 4rMenB+OMV NZ | Naive_4042 |
|---|---|---|---|
| 44/76-SL strain (N = 11,14,37) | 100 (72 to 100) | 93 (66 to 100) | 54 (37 to 71) |
| 5/99 strain (N = 12,14,38) | 100 (74 to 100) | 100 (77 to 100) | 76 (60 to 89) |
| NZ98/254 strain (N = 13,14,37) | 23 (5 to 54) | 71 (42 to 92) | 11 (3 to 25) |
| M10713 strain (N = 11,14,38) | 18 (2 to 52) | 36 (13 to 65) | 5 (1 to 18) |
The persisting serum bactericidal antibody titers in children (at 60 months of age), twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months of age) is compared with the antibody titers in vaccine -naïve subjects of the same age and reported as GMTs.
| Titers | 4rMenB | 4rMenB+OMV NZ | Naive_6062 |
|---|---|---|---|
| 44/76-SL strain (N = 9,12,46) | 9.37 (2.47 to 36) | 4.69 (1.98 to 11) | 1.09 (0.96 to 1.25) |
| 5/99 strain (N = 9,11,46) | 334 (186 to 599) | 119 (56 to 252) | 1.17 (0.96 to 1.42) |
| NZ98/254 strain (N = 10,12,46) | 1 (1 to 1) | 1.63 (0.86 to 3.08) | 1 (1 to 1) |
| M10713 strain (N = 8,11,45) | 4.96 (1.03 to 24) | 5.51 (2.19 to 14) | 8.09 (5.13 to 13) |
The percentage of subjects (60 months of age) with persisting hSBA titers ≥4, twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months of age) are compared with hSBA response in vaccine-naïve subjects of the same age.
| percentages of subjects | 4rMenB | 4rMenB+OMV NZ | Naive_6062 |
|---|---|---|---|
| 44/76-SL strain (N = 9,12,46) | 67 (30 to 93) | 67 (35 to 90) | 4 (1 to 15) |
| 5/99 strain (N = 9,11,46) | 100 (66 to 100) | 100 (72 to 100) | 4 (1 to 15) |
| NZ98/254 strain 10, 12, 46) | 0 (0 to 31) | 17 (2 to 48) | 0 (0 to 8) |
| M10713 strain (N = 8,11,45) | 50 (16 to 84) | 45 (17 to 77) | 67 (51 to 80) |
The percentage of subjects with hSBA titers ≥4 after two catch-up doses of rMenB+OMV NZ vaccine when given either at- 40 \& 42 months or 60 \& 62 months of age is reported.
| percentages | Naive_4042 | Naive_6062 |
|---|---|---|
| 44/76-SL strain (N = 30,34) | 100 (88 to 100) | 100 (90 to 100) |
| 5/99 strain (N = 31,34) | 100 (89 to 100) | 100 (90 to 100) |
| NZ98/254 strain (N=31, 35) | 90 (74 to 98) | 89 (73 to 97) |
| M10713 strain (N = 29,33) | 72 (53 to 87) | 97 (84 to 100) |
The serum bactericidal antibody response in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at- 40 \& 42 months or 60 \& 62 months of age are reported as GMTs.
| Titers | Naive_4042 | Naive_6062 |
|---|---|---|
| 44/76-SL strain (N = 30,34) | 74 (57 to 94) | 83 (67 to 103) |
| 5/99 strain (N = 31,34) | 247 (188 to 323) | 331 (254 to 432) |
| NZ98/254 strain (N = 30,35) | 16 (11 to 23) | 14 (9.81 to 21) |
| M10713 strain (N = 29,33) | 8.91 (5.19 to 15) | 44 (33 to 57) |
The percentages of subjects with four-fold increase in hSBA titers over baseline against N meningitidis serogroup B one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 \& 42 months or 60 \& 62 months of age.
| percentages of subjects | Naive_4042 | Naive_6062 |
|---|---|---|
| 44/76-SL strain (N = 29,34) | 100 (88 to 100) | 100 (90 to 100) |
| 5/99 strain (N = 31,34) | 100 (89 to 100) | 100 (90 to 100) |
| NZ 98/254 strain (N = 30,35) | 73 (54 to 88) | 69 (51 to 83) |
| M10713 strain (N = 29,32) | 24 (10 to 44) | 53 (35 to 71) |
The serum bactericidal antibody response in children at 60 months of age who had received two catch-up doses of rMenB+OMV NZ vaccine at- 40 \& 42 months age is reported as GMTs.
| Titers | Naive_4042 |
|---|---|
| 44/76-SL strain | 2.73 (1.54 to 4.84) |
| 5/99 strain | 24 (16 to 35) |
| NZ98/254 strain | 1 (1 to 1) |
| M10713 strain (N = 23) | 14 (6.78 to 27) |
Persisting hSBA titers ≥4 in children at 60 months of age, who had received two catch-up doses of rMenB+OMV NZ vaccine at 40 \& 42 months age is reported.
| percentages of subjects | Naive_4042 |
|---|---|
| 44/76-SL strain | 38 (19 to 59) |
| 5/99 strain | 100 (86 to 100) |
| NZ98/254 strain | 0 (0 to 14) |
| M10713 strain (N = 23) | 83 (61 to 95) |
The persisting geometric mean antibody concentrations (GMCs) against vaccine antigen 287-953 in children (at 40 months of age), twenty-eight months after completion of primary vaccination with either rMenB or rMen+OMV NZ vaccines, are compared with the GMCs in vaccine-naïve children. GMCs against vaccine antigen 287-953 were measured using enzyme linked immunosorbent assay (ELISA).
| concentrations (AU/mL) | 4rMenB | 4rMenB+OMV NZ | Naive_4042 |
|---|---|---|---|
| Geometric Mean Antibody Concentrations in Children (at 40 Months of Age), Twenty Eight Months After Completing Primary Vaccination. | 86 (43 to 173) | 103 (61 to 174) | 27 (22 to 35) |
The GMCs against vaccine antigen 287-953, in children one month after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccine , is compared with GMCs following one catch-up dose of rMenB+ OMV NZ in children at 40 months.
| concentrations (AU/mL) | 4rMenB | 4rMenB+OMV NZ | Naive_4042 |
|---|---|---|---|
| Geometric Mean Antibody Concentrations in Children, After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age. | 5187 (2924 to 9204) | 3662 (2065 to 6491) | 83 (52 to 133) |
The persisting GMCs against vaccine antigen 287-953 in children (at 60 months of age), twenty months after receiving a booster dose of either rMenB or rMenB+OMV NZ vaccine (at 40 months), are compared with GMCs in vaccine-naïve children of same age.
| concentrations (AU/mL) | 4rMenB | 4rMenB+OMV NZ | Naive_6062 |
|---|---|---|---|
| Geometric Mean Antibody Concentrations in Children (at 60 Months of Age), Twenty Months After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine | 772 (395 to 1512) | 358 (201 to 640) | 25 (19 to 33) |
The GMCs against vaccine antigen 287-953 in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at 40- \& 42- months or 60- \& 62- months of age are reported.
| concentrations (AU/mL) | Naive_4042 | Naive_6062 |
|---|---|---|
| Geometric Mean Antibody Concentrations in Children After Two Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 Months or 60 Months of Age. | 612 (329 to 1139) | 2164 (1663 to 2817) |
Persistence of GMCs against vaccine antigen 287-953 in children (60 months of age), eighteen months after two catch-up doses of rMenB+OMV NZ vaccine given at 40 months of age.
| concentrations (AU/mL) | Naive_4042 |
|---|---|
| Geometric Mean Antibody Concentrations in Children (at 60 Months), Eighteen Months After Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine. | 87 (63 to 120) |
The percentage of subjects with four fold increase in GMCs over baseline against vaccine antigen 287-953 one month after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccine, is compared with responses following one catch-up dose of rMenB+OMV NZ in children at 40 months.
| percentages of subjects | 4rMenB | 4rMenB+OMV NZ | Naive_4042 |
|---|---|---|---|
| Percentage of Subjects With Four Fold Increase in Geometric Mean Antibody Concentrations , After a Single Booster Dose of rMenB or rMenB+OMV NZ Vaccine Given at 40 Months of Age | 100 (77 to 100) | 100 (77 to 100) | 21 (10 to 37) |
The percentages of subjects with four-fold increase in GMCs over baseline against vaccine antigen 287-953, one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 \& 42 months or 60 \& 62 months of age.
| percentages of subjects | Naive_4042 | Naive_6062 |
|---|---|---|
| Percentage of Subjects With 4-fold Increase in Geometric Mean Antibody Concentrations, After Two Catch-up Doses of rMenB+OMV NZ Vaccine Given One Month Apart Either at 40 or 60 Months of Age | 77 (59 to 90) | 97 (85 to 100) |
The safety and tolerability of a two doses of rMenB+OMV NZ vaccine in children when given either at 40 \& 42 months or 60 \& 62 months of age is assessed in terms of number of subjects with solicited local and systemic reactions following vaccination.
| participants | Naive_4042 | Naive_6062 |
|---|---|---|
| Local | 39 | 48 |
| Injection-site pain | 38 | 46 |
| Injection-site erythema | 38 | 46 |
| Injection-site swelling | 19 | 32 |
| Injection-site induration | 26 | 28 |
| Systemic | 39 | 48 |
| Change in eating habits | 20 | 15 |
| Sleepiness | 26 | 26 |
| Vomiting | 4 | 7 |
| Diarrhea | 4 | 4 |
| Irritability | 29 | 29 |
| Headache | 8 | 12 |
| Arthralgia | 13 | 24 |
| Rash | 3 | 5 |
| Fever (≥38°C) | 10 | 10 |
| Other | 21 | 26 |
| Antipyretic Preventive medication used | 24 | 29 |
| Antipyretic Treatment medication used | 8 | 12 |
| Temperature(≥40°C) | 1 | 0 |
| Medically attended fever | 1 | 0 |
Collected over Solicited AEs were collected from Day 1 to Day 7 after each vaccination, SAEs and other unsolicited AEs were collected throughout the study [approximately 20 months for Groups rMenB; rMenB+OMV NZ and Naive_4042 and Days 1-91 for Naive_6062 group].. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 4rMenB | — | 1/16 (6.3%) | 15/16 (93.8%) |
| 4rMenB+OMV NZ | — | 1/14 (7.1%) | 14/14 (100%) |
| Naive_4042 | — | 4/41 (9.8%) | 41/41 (100%) |
| Naive_6062 | — | 1/48 (2.1%) | 48/48 (100%) |
| Event | 4rMenB | 4rMenB+OMV NZ | Naive_4042 | Naive_6062 |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/16 | 1/14 | 0/41 | 0/48 |
| LymphadenitisBlood and lymphatic system disorders | 1/16 | 0/14 | 0/41 | 0/48 |
| VomitingGastrointestinal disorders | 0/16 | 0/14 | 1/41 | 0/48 |
| Croup infectiousInfections and infestations | 0/16 | 0/14 | 1/41 | 0/48 |
| GastroenteritisInfections and infestations | 0/16 | 0/14 | 1/41 | 0/48 |
| EncephalitisNervous system disorders | 0/16 | 0/14 | 1/41 | 0/48 |
| Febrile convulsionNervous system disorders | 0/16 | 0/14 | 1/41 | 0/48 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/16 | 0/14 | 0/41 | 1/48 |
| Event | 4rMenB | 4rMenB+OMV NZ | Naive_4042 | Naive_6062 |
|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 13/16 | 14/14 | 40/41 | 46/48 |
| Injection site painGeneral disorders | 10/16 | 12/14 | 38/41 | 46/48 |
| IrritabilityGeneral disorders | 8/16 | 11/14 | 29/41 | 29/48 |
| Injection site indurationGeneral disorders | 11/16 | 5/14 | 26/41 | 28/48 |
| Injection site swellingGeneral disorders | 9/16 | 6/14 | 20/41 | 32/48 |
| SomnolenceNervous system disorders | 6/16 | 6/14 | 26/41 | 26/48 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/16 | 3/14 | 13/41 | 24/48 |
| Eating disorderPsychiatric disorders | 5/16 | 5/14 | 20/41 | 15/48 |
| HeadacheNervous system disorders | 2/16 | 1/14 | 8/41 | 13/48 |
| PyrexiaGeneral disorders | 4/16 | 1/14 | 11/41 | 10/48 |
| Age, Continuous(months) | 4rMenB | 4rMenB+OMV NZ | Naive_4042 | Naive_6062 | Total |
|---|---|---|---|---|---|
| Mean | 42.8 ± 1.1 | 43.1 ± 0.9 | 41.7 ± 1.7 | 61.3 ± 0.7 | 50.0 ± 9.5 |
| Sex: Female, Male(Participants) | 4rMenB | 4rMenB+OMV NZ | Naive_4042 | Naive_6062 | Total |
|---|---|---|---|---|---|
| Female | 8 | 11 | 22 | 21 | 62 |
| Male | 8 | 3 | 19 | 28 | 58 |
The record gives a start of Feb 2010, a primary completion of Sep 2010 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine